scispace - formally typeset
D

Do Young Kim

Researcher at Yonsei University

Publications -  737
Citations -  18320

Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.

Papers
More filters
Proceedings ArticleDOI

A scalable and persistent key-value store using non-volatile memory

TL;DR: This work proposes a novel hybrid key-value scheme that consists of NVRAM and dynamic random-access memory, which supports a higher level of data persistence while maintaining high performance and provides scalability allowing NVRam and DRAM to be used without possibility of data loss.
Journal ArticleDOI

Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B.

TL;DR: In this article, the authors investigated whether the combined use of ultrasonography (US) and transient elastography (TE) is beneficial for the risk assessment of hepatocellular carcinoma (HCC) and liver-related events in patients with chronic hepatitis B (CHB).
Journal ArticleDOI

HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines.

TL;DR: The results suggest that HKR3 induced regulation of cell cycle through hTERT inhibition and CDKN2A activation will facilitate further exploration of the pathways regulating human telomerase activity in HCC cell lines.
Journal ArticleDOI

The formation of sub-10 nm nanohole array on block copolymer thin films on gold surface using surface neutralization based on O2 plasma treatment and self-assembled monolayer

TL;DR: In this paper, self-assembled blockcopolymer (BCP) thin films having cylindrical nanoholes were prepared on gold by surface neutralization using selfassembled monolayer (SAM).
Journal ArticleDOI

Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma

TL;DR: In this paper, the authors compared the clinical efficacies of hepatic arterial infusion chemotherapy (HAIC) vs. sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC).